今日特讯！智富资源投资(00007)全年业绩延期至7月31日或以前刊发，公司正与核数师紧密合作加快审计进度

智富资源投资(00007)全年业绩延期至7月31日或以前刊发，公司正与核数师紧密合作加快审计进度

香港，2024年6月18日 - 智富资源投资(00007)今日发布公告，宣布公司全年业绩将于7月31日或以前刊发，较此前预计的5月14日延迟。公司表示，延迟刊发业绩的原因是物业开发项目的估值工作需要额外时间。

智富资源投资是一家主要从事物业开发、投资及管理的香港公司。公司于2023年12月31日止的年度内，物业开发项目的估值工作出现了一些复杂情况，需要额外时间进行核实和调整。因此，公司需要延迟刊发全年业绩，以确保财务信息的准确性。

公司表示，正与核数师紧密合作，以尽快完成审计程序。根据公司目前所获得的资料，预计全年业绩将于7月31日或以前刊发。

智富资源投资的延迟刊发业绩可能会对公司股价造成一定影响。截至2024年6月18日收盘，智富资源投资股价报0.032港元，跌幅0.99%。

以下是一些可能影响智富资源投资业绩的因素：

• 中国房地产市场持续低迷，导致物业开发项目销售额下降和利润率缩窄。
• 全球通胀上升，导致建筑材料和人工成本上升，增加物业开发项目的成本。
• 融资成本上升，导致公司财务费用增加。

智富资源投资未来的发展前景尚不明朗，投资者应谨慎投资。

以下是一些可能影响智富资源投资未来发展的因素：

• 中国政府的房地产调控政策
• 中国经济整体走势
• 全球金融市场状况

投资者应密切关注智富资源投资的后续公告，并结合自身情况进行投资决策。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.